Aditya Dubey, MD
Pulmonary Disease · Dulles, VANPI 1922203116
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,979 of the $21,149 with a category attached, or 70.8%. 47 manufacturers reported payments, led by United Therapeutics Corporation at 32.1% of the total.
Across 612 payments — averaging $34.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$7K
- AstraZeneca$4K
- GSK$2K
- Inspire Medical Systems, Inc.$825
- Regeneron Healthcare Solutions, Inc.$786
- Grifols USA, LLC$611
- plus $6K from 41 others
Across 14 payments — averaging $5772.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$81K
What the payments were for
- Consulting fees$4,81023%
- Travel & lodging$9855%
- Food & beverage$14,97971%
- Education$3742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$406
- Inspire$400
- TEZSPIRE$379
- GALAXY$352
- NUCALA$246
- REMODULIN$150
- ZEPHYR ENDOBRONCHIAL VALVE$145
- PULMONX CHARTIS TABLET CONSOLE$145
- CHARTIS CATHETER$145
- ZEPHYR DELIVERY CATHETER$145
- AIRSUPRA$126
- OPDIVO$125
- TRELEGY ELLIPTA$123
- FASENRA$115
How this compares
$21,149 in reported general payments places this provider in the 85th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 41 | $472,973 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 581 | $470,245 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $83,059 |
| Spiriva RespimatTiotropium Bromide | 113 | $78,212 |
| Breo ElliptaFluticasone/Vilanterol | 129 | $75,624 |
| TezspireTezepelumab-Ekko | 12 | $53,731 |
| NucalaMepolizumab | 13 | $46,037 |
| Advair HfaFluticasone Propion/Salmeterol | 89 | $45,235 |
| Incruse ElliptaUmeclidinium Bromide | 50 | $32,672 |
| DuleraMometasone/Formoterol | 68 | $27,817 |
| EliquisApixaban | 22 | $17,187 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $14,843 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 108 | $12,362 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $11,368 |
| Wixela InhubFluticasone Propion/Salmeterol | 91 | $10,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $2,161 | $642,945815 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $539 | $562,553181 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $3,527 | $143,350131 claims |
| PfizerEliquis | $13 | $17,18722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Dulles
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
- Himanshu DesaiChesapeake$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.